STAT | Reporting from the frontiers of health and medicine Follow STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and more Patient advocates and some experts are expressing growing alarm over the perceived risks of a Neurocrine Biosciences rare disease drug https://www.statnews.com/pharmalot/2026/10/13/neurocrine-rare-disease-drug-concerns-pharma-payments-to-doctors/ statnews.com
